Skip to content
Home/Companies/Biotech/Bambusa Therapeutics

Bambusa Therapeutics

Biotech·United States·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Bambusa Therapeutics?

Bambusa Therapeutics is an American Biotech company, currently owned by Athos since 2025.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
Athos
Investor
Athos
Athos Evergreen Life Sciences · 2001 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Athos Evergreen Life Sciences

Other portfolio companies in the same fund.

Doctolib
Doctolib
Active
HealthTechFrance· 2026
AAVantgarde Bio
Active
BiotechItaly· 2025
AMSilk
Active
BiotechGermany· 2025
Antheia
Active
BiotechUS· 2025
NexWafe
NexWafe
Active
ClimateTechGermany· 2023
Formycon
Formycon
Active
BiotechGermany· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Bambusa Therapeutics?

Bambusa Therapeutics is currently owned by Athos, through Athos Evergreen Life Sciences, since 2025.

When did Athos acquire Bambusa Therapeutics?

Athos acquired Bambusa Therapeutics in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue